Parkinson's Disease Clinical Trials in New Haven, Connecticut

5 studies are recruiting for parkinson's disease in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

   This is an observational study in which data are collected and studied from Parkinson's disease patients who have movement symptoms despite taking standard Parkinson's medications. In observational studies, observations are made without any changes to the participant's healthcare or treatment plan.…

   Stage

   Not phased

   Ages

   45 to 75

   Site

   Yale School of Medicine's Stephen and Denise Adams Center for Parkinson's Disease Research, New Haven, Connecticut

   Locations

   27 in total

   Run by

   Bayer

   See if you can join NCT07330258 on ClinicalTrials.gov

2. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

   The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

   Stage

   Phase 3

   Ages

   50 to 85

   Site

   Institute for Neurodegenerative Disorders, New Haven, Connecticut

   Locations

   192 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07174310 on ClinicalTrials.gov

3. A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

   The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study consists of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Dose (MAD) stu…

   Stage

   Phase 1

   Ages

   30 to 80

   Site

   XingImaging LLC, New Haven, Connecticut

   Locations

   16 in total

   Run by

   Prevail Therapeutics

   See if you can join NCT06565195 on ClinicalTrials.gov

4. Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

   The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, [18F]PI-2620, and a high resolution PET camera, NeuroEXPLORER.

   Stage

   Phase 2

   Ages

   45 to 85

   Site

   Institute for Neurodegenerative Disorders / XingImaging, LLC, New Haven, Connecticut

   Run by

   Michael J. Fox Foundation for Parkinson's Research

   See if you can join NCT07020026 on ClinicalTrials.gov

5. Imaging Depression in Parkinson's Disease

   The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.

   Stage

   Phase 2

   Ages

   40 to 80

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT06402955 on ClinicalTrials.gov